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Abstract
Endothelial dysfunction or loss is the early event that leads to a host of severe cardiovascular diseases, such as
atherosclerosis, hypertension, brain stroke, myocardial infarction, and peripheral artery disease. Ageing is regarded
among the most detrimental risk factor for vascular endothelium and predisposes the subject to atheroscleorosis
and inflammatory states even in absence of traditional comorbid conditions. Standard treatment to restore blood
perfusion through stenotic arteries are surgical or endovascular revascularization. Unfortunately, ageing patients are
not the most amenable candidates for such interventions, due to high operative risk or unfavourable vascular
involvement. It has recently been suggested that the transplantation of autologous bone marrow-derived
endothelial progenitor cells (EPCs) might constitute an alternative and viable therapeutic option for these
individuals. Albeit pre-clinical studies demonstrated the feasibility of EPC-based therapy to recapitulate the diseased
vasculature of young and healthy animals, clinical studies provided less impressive results in old ischemic human
patients. One hurdle associated to this kind of approach is the senescence of autologous EPCs, which are less
abundant in peripheral blood and display a reduced pro-angiogenic activity. Conversely, umbilical cord blood
(UCB)-derived EPCs are more suitable for cellular therapeutics due to their higher frequency and sensitivity to
growth factors, such as vascular endothelial growth factor (VEGF). An increase in intracellular Ca2+ concentration is
central to EPC activation by VEGF. We have recently demonstrated that the Ca2+ signalling machinery driving the
oscillatory Ca2+ response to this important growth factor is different in UCB-derived EPCs as compared to their
peripheral counterparts. In particular, we focussed on the so-called endothelial colony forming cells (ECFCs), which
are the only EPC population belonging to the endothelial lineage and able to form capillary-like structures in vitro
and stably integrate with host vasculature in vivo. The present review provides a brief description of how exploiting
the Ca2+ toolkit of juvenile EPCs to restore the repairative phenotype of senescent EPCs to enhance their
regenerative outcome in therapeutic settings.
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Introduction
Senescence and aging involving several mechanisms like
oxidative stress and elevated ROS (Reactive oxygen spe-
cies). They has been implicated in cancer, diabetes, neu-
rodegenerative, cardiovascular and other diseases [1,2].
Several stressors, including high-caloric diets, physical
activity, chemicals, drugs and pollutants, induce oxidants
overproduction [3]. The endothelium forms a multifunc-
tional signal transducing surface that lines the luminal
surface of both blood vessels and cardiac chambers,
thereby maintaining cardiovascular homeostasis [4].
Such strategic location places endothelial cells (ECs) in
the most suitable condition to properly govern blood
pressure, coagulation and fibrinolysis, vascular inflam-
matory reactions, permeability of the vessel wall, and
angiogenesis [5,6]. The endothelial monolayer modulates
such different functions due to its ability to synthesize
and release a myriad of agents that regulate vasomotor
function, trigger inflammatory processes, and affect hae-
mostasis [5,7]. Nitric oxide (NO), prostacyclin (PGI2),
carbon monoxide (CO), hydrogen sulphide (H2S), epox-
yeicosatrienoic acids (EETs), and adenosine represent
the main vasodilatory factors produced by vascular ECs
[7,8], while vasoconstrictors include endothelin-1 (ET-1),
angiotensin II (Ang II), thromboxane A2 (TXA2), prosta-
glandin H2 (PGH2), and reactive oxygen species (ROS)
[6,8]. Furthermore, ECs directly communicate with
the underlying smooth muscle cells (SMCs) through
myoendothelial gap junctions which spread endothelial-
dependent hyperpolarization (the so-called endothelium-
dependent hyperpolarizing factor, EDHF) and reduce the
vascular tone [9]. In addition, cardiac microvascular ECs
adjust myocardial contractility according to incoming
inputs by releasing paracrine mediators, such as NO, ET-
1 and prostanoids [10]. As a consequence, endothelial
damage attenuates the vaso-relaxing, anti-thrombotic,
and anti-inflammatory properties of the endothelial sheet
and causes a shift to conditions prone to vasoconstric-
tion, coagulation, and inflammation [6,8]. This chain of
events depends on reduction in NO bioavailability and
the alterations in the production of most, if not all, the
humoral and electrical factors described above [6,11].
In addition, vascular ECs prevent SMC proliferation by
liberating several growth inhibitors, such as NO and
prostacyclins [12,13]. Endothelial dysfunction may thus
promote vessel thickening by stimulating SMCs to switch
from a non-contractile phenotype and migrate from the
tunica media towards the inner lumen [11,12]. This
process induces the inward remodeling of vascular archi-
tecture, with variable degrees of arteriolar narrowing
in the chronic phase, the so-called restenosis [14]. Over-
all, endothelial dysfunction leads to the impairment of
blood perfusion to vital and peripheral organs and
compromises cardiovascular homeostasis [6,11-13]. This
leads to the development and progression of potentially
lethal cardiovascular diseases, such as hypertension,
atherosclerosis, atherothrombosis, myocardial infarction,
brain stroke and vascular forms of renal failure [6,11].
Tissue perfusion through stenotic supplying arteries in
patients suffering symptomatic occlusive atherosclerosis
or surviving to the acute phase of a heart attack may be
restored by a number of surgical approaches. These
include angioplasty, deployment of intracoronary stents,
percutaneous coronary intervention (PCI), and coronary
artery bypass surgery. These procedures, however, may
further affect the integrity of the endothelial monolayer
and, in the long term, may cause thrombi formation and
neointimal hyperplasia. The subsequent shrinkage of the
arterial wall severely limits the beneficial outcome of
reconstructive surgery and leads to in-stent restenosis-
related heart disease [15-17]. In addition, ischemia
resulting from microvascular or endothelial dysfunction
results in obstructive peripheral artery disease (PAD), a
major cause of morbidity and mortality in the western
world, by accounting for up to 30% of deaths worldwide
[16]. In its most advanced form, critical limb ischemia
(CLI), the insufficient blood flow to lower extremities is
associated to atypical leg pain and intermittent claudica-
tion, and may progress to tissue lost, gangrene and
amputation when either surgical or endovascular revas-
cularisation fail to restore local perfusion [16,17]. The
wide array of unmet medical needs in the treatment of
cardiovascular diseases boosted the search for alternative
strategies to stimulate therapeutic angiogenesis by reca-
pitulating the vascular network within the ischemic
organ [4-6]. The adult bone marrow (BM) is a rich
reservoir of progenitor and stem cells, which possess the
capability for self-renewal and differentiation into organ-
specific cell types [7]. As shown in several animal mod-
els, transplantation of these cells may reconstitute organ
systems, a therapeutic approach termed cell-based ther-
apy (CBT). The discovery that non-resident cells contri-
bute to vascular repair paved the way for unexpected
therapeutic options, since these cells can be harvested,
expanded and re-inoculated to boost vascular regenera-
tion [16-19]. It has now been established that endothe-
lial progenitor cells (EPCs) are among the most suitable
bone marrow-derived cell populations to regenerate
ischemic organs and hold great promise to meet the
untreatable clinical demands of cardiovascular disorders
[20-24]. Unfortunately, both the frequency and the pro-
angiogenic activity of circulating EPCs are dramatically
impaired in the elderly, thereby limiting the use of auto-
logous CBT in ageing population [25,26]. Recent work
conducted by our group has disclosed the master role
served by intracellular Ca2+ signalling in controlling
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EPC proliferation, homing and assembly into capillary-
like structures. The present review will briefly address
the possibility to exploit specific components of the Ca2+
toolkit to improve the regenerative outcome of EPC-
based therapy in ageing patients.
Ageing is relevant risk factor for vascular
endothelium: causes and detrimental impact on
the outcome of therapeutic treatment of
ischemic diseases
Ageing is regarded among the most detrimental threatens
for vascular endothelium and, therefore, human health.
The impairment of EC function is a progressive phenom-
enon that starts in the middle age, has been termed
endothelial senescence and may occur in absence of any
other cardiovascular risk factor [25-27]. Age-related
endothelial dysfunction is associated to deterioration in
the balance between vasodilator and vasoconstriction
mediators liberated by vascular ECs. In females postme-
nopausal hypoestrogenism may cause an increase in
arterial vascular tone through a reduction of vasodilator
peptides and an increase in vasoconstrictor peptides in
the arterial-wall termination of the autonomous system
in some anatomical districts leading several symptoms.
These changes in neuropeptide content in the arterial
walls might represent a new mechanism underlying the
negative effects of menopause on the cardiovascular sys-
tem [28-30]. Vascular ECs imbalance is featured by a
progressive decrease of NO bioavailability and an
enhanced production of cyclooxygenase-derived vasocon-
strictor factors, such as TXA2 and PGH2 [6,31]. Further-
more, a decline in EDHF contribution to endothelial
dilatation of human arteries comes about in different vas-
cular regions [26], albeit studies conducted on murine
models do not conclusively support this notion [25]. The
decrease in endothelial NO synthesis with ageing is paral-
leled by an elevation in O2 production and in the subse-
quent generation of ROS, pivotal among which are the
superoxide radical (O2•
-) and the peroxynitrite anion
(ONOO-) [25,26]. The severe oxidative stress imposed on
the endothelial monolayer in elderly contributes to
rapidly inactivate NO, which may be scavenged by O2•
-,
and is accompanied by a low-grade chronic inflammatory
state, thereby originating the so-called “inflammaging”,
which involves up-regulation of cellular adhesion mole-
cules, an increase in endothelial-leukocyte interactions
and permeability, as well as alterations in the secretion of
autocrine/paracrine cytokines, which are pivotal to
inflammatory responses [25,32]. Among these, an
increase in the circulating levels of TNF-a, IL-1b, and
members of the super-family of IL-6, as well as of mito-
chondrial-derived ROS, is the primum movens for the
nuclear factor-kappa B (NF-kB)-mediated transcription
of endothelial pro-inflammatory genes that lead to
vascular dysfunction [33]. It is, therefore, not surprising
that age-related oxidative stress and inflammation may
act as powerful pro-atherogenic factors even in the
absence of any other cardiovascular risk factor, such as
smoking, hypertension, obesity, diabetes, and so on
[25,26,33]. Consistent with the pro-atherosclerotic remo-
delling of the vascular structure, senescent ECs undergo
a dramatic alteration in their morphological phenotype,
by adopting an enlarged and flattened morphology and
displaying organelle hyperplasia [34]. Furthermore, they
express senescence-associated enzymes, such as the
acidic b-galactosidase (SA-b-gal). Last, but not least, age-
ing ECs loose their capability to proliferate and to substi-
tute adjacent/neighbouring damaged cells, thereby
aggravating the impact of endothelial detachment from
the vessel wall, that may be provoked by turbulent blood
flow, higher incidence of apoptosis or iatrogen interven-
tions [31]. The exit from the cell cycle and the permanent
growth arrest are due to an impaired telomerase activity
or telomere shortening as a result of the “inflammaging”
state suffered by the vascular wall [11,25,31]. The limited
capacity for endothelium to regenerate the denuded vas-
cular wall and to undergo angiogenesis renders elderly
patients less prone to receive aggressive coronary revas-
cularisation and augments the risk of adverse outcomes
with PCI, i.e. late in-stent restenosis [15]. Moreover,
elderly patients with symptomatic ischemic heart disease
may not be amenable for surgical revascularization due
to accompanying comorbidities or small vessel disease
[16,17]. Likewise, the strengths and limitations of surgical
revascularization in elderly patients affected by obstruc-
tive vascular diseases are well known. They are, therefore,
left with few, if any, effective therapeutic methods to alle-
viate symptom, restore distal perfusion and preserve tis-
sue viability [15-17]. Therapeutic angiogenesis represents
an alternative strategy to generate new blood vessel
growth, thereby promoting neovascularization and tissue
repair, in patients who are not amenable for vascular
reconstructive surgery [16,17,35]. Currently, there are
three major indications for which angiogenic therapies
are in clinical use: 1) chronic wounds (e.g. diabetic lower
extremity ulcers, venous leg ulcerations, pressure ulcers,
arterial ulcers); 2) PAD; and 3) ischemic heart disease. In
such conditions, the therapeutic goal is to stimulate
angiogenesis to improve perfusion, deliver survival fac-
tors to sites of tissue repair, mobilize regenerative stem
cell populations, and ultimately, restore form and func-
tion to the tissue [16-18,35,36]. Cellular-based strategies
are now referred to as the most promising approach to
treat disorders of inadequate blood perfusion by injecting
the most suitable cell population to recapitulate the
damaged vascular network [16-18,22,36]. We refer the
reader to a number of exhaustive and recent review
describing the most popular cell populations and
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methods of delivery utilized in both pre-clinical studies
and clinical trials [16-18,24,27,36-39]. In the following
paragraphs, we will focus on circulating EPCs and will
speculate on the possibility to utilize their Ca2+ machin-
ery to overcome the hurdles related to EPC senescence
and improve the outcome of CBT.
Endothelial progenitor cells as an alternative tool
to restore blood perfusion in ischemic tissues:
umbilical cord blood as a better cell source as
compared to aged peripheral blood
Endothelial progenitor cells (EPCs) are mobilized from
bone marrow to replace the ECs sloughed off from the
vascular wall as a result of either apoptosis or a trau-
matic vascular injury [20-24,40]. Not only EPCs physi-
cally integrate within the lesioned monolayer. They do
stimulate local angiogenesis by the paracrine release of
growth factors and chemokines, such as vascular
endothelial growth factor (VEGF) and stromal derived
factor-a (SDF-a), that induce ECs from adjacent capil-
laries to sprout towards the ischemic area [20-24,40].
Under normal conditions, EPCs are embedded in a
microenvironment (niche) of BM, so that the number of
circulating EPCs is relatively small in absence of any
cardiovascular trauma. Vascular insult or disease causes
the up-regulation of the hypoxia inducible factor a
(HIFa), a transcription factor driving the local expres-
sion of the cytokines - VEGF, SDF-a, and erythropoietin
(EPO) - that stimulate EPC release from the stem cell
niche into peripheral blood (PB). EPCs in turn follow
the cytokine gradient to the site of arterial injury, where
they adhere to the denuded extracellular matrix and
replace lost cells by acquiring a mature endothelial phe-
notype [22,23,41]. Unfortunately, the term EPC does not
refer to a unique cell population, with an identified
panel of surface antigens or makers or a well character-
ized transcriptomic profile; currently, EPC is a definition
that encompasses a broad range of cell subsets, which
may all stimulate angiogenesis in vivo, but are not
necessarily truly committed endothelial progenitors. We
refer the reader to a number of recent reviews addres-
sing the phenotypic and functional characterization of
the three main populations of putative circulating EPCs,
i.e. colony forming units-ECs (CFU-ECs), circulating
angiogenic cells (CACs), and endothelial colony forming
cells (ECFCs) [20,21,23,40,41]. CFU-ECs and CACs
belong to the hematopoietic lineage and are able to
induce therapeutic angiogenesis by paracrine assistance
of local ECs via the production of VEGF and SDF1-a.
Conversely, ECFCs express all the typical surface anti-
gens of the endothelial lineage (CD105, CD31, CD144,
von Willebrand factor, VEGFR-2) but not the CD45 and
CD14 antigens, which feature the hematopoietic pheno-
type. In addition, ECFCs exhibit a robust clonogenic
proliferative capacity and assembly into capillary-like
networks both in vitro and in vivo. In particular, ECFCs
stably integrate within the vasculature of the host ani-
mal, thereby permitting blood flow, when suspended in
a collagen scaffold and transplanted into immunodefi-
cient mice [20-23,40-43]. Therefore, ECFCs are regarded
as the most suitable EPC subtype to replace lost ECs
and to promote vascular healing in clinical settings. It
should, however, be pointed out that ECFCs are not
only mobilized from BM; a complete hierarchy of highly
proliferative ECFCs has indeed been described in the
vessel wall of human arteries [20], albeit their contribu-
tion to endothelial repair in vivo has not been experi-
mentally verified.
Once understood that pre-clinical and clinical studies
conducted to assess the regenerative potential of circu-
lating EPCs are largely heterogeneous as respect to their
identification, characterisation and functional role, an
evident link has been established between the frequency
of EPCs in peripheral blood and the propensity for car-
diovascular disease. A decrease in the level of circulating
(CD34+ VEGFR-2+) EPCs is a reliable and independent
predictor of an increased risk for atherosclerosis, and
has been associated to the increase in intima-media
thickness that features the atherosclerotic lesions in
distinct vascular districts [18,23,38]. Similarly, lower
CD34+/CD133+/VEGFR-2+ EPC counts have been
reported in patients with multivessel coronary artery
disease [23,37,38]. Likewise, a rapid and significant
increase in EPC numbers, detected by utilising 5 differ-
ent approaches (CD34+, D34+/CD117+, CD34+/CXCR4+,
CD34+/CD38+ and CD34+/CD45+), has been reported
after the onset of ischemia in acute myocardial infarc-
tion [22,38]. Notably, the higher frequency of progenitor
cells was positively correlated with an improvement of
ventricular function and negatively correlated with myo-
cardial necrosis markers in at least 2 of these studies
[22]. In agreement with hypoxia acting as a primary sti-
mulator of EPC mobilization, a significant rise in EPC
(CD34+/CD133+/VEGFR-2+) numbers occurs in patients
with unstable angina and in mild heart failure (NYHA
class I-II), whereas their release in circulation is dam-
pened in subjects with advanced heart failure (NYHA
III-IV). At the same way, CD34+/CD133+/VEGFR-2+
EPCs increase during the moderate phase of PAD, while
they significantly decrease below the control levels in
the advanced phase [44]. These observations have been
accompanied by a myriad of pre-clinical studies and
clinical trials which were devoted to assess the feasibility
of utilising EPCs in regenerative therapy. In more detail,
it was demonstrated that: 1) ex vivo expanded human
EPCs increased capillary density and reduced the rate of
limb loss when implanted into murine models of hind
limb ischemia; 2) exogenously administered EPCs
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increased the extent of neovascularisation and improved
the left ventricular ejection fraction (LVEF) when
injected intravenously into rats with myocardial ische-
mia; 3) infusion of autologous EPCs restored endothelial
functions and improved vascularisation in patients suf-
fering from PAD and limb ischemia, respectively;
4) transplantation of PB-derived EPCs in patients who
underwent AMI or suffered from chronic myocardial
ischemia led to an improvement in LVEF, a reduction in
infarct size, and an increase in capillary density; 5)
EPCs-capturing stents, which are based on CD34 anti-
body coated device, accelerate the re-endothelialization
of the damaged arterial segment and reduce the risk of
in-stent restenosis after PCI in both animal models and
in human subjects [18,24,36-39,45,46]. On the basis of
these evidences, EPCs has been put forward as the most
promising novel therapeutics of peripheral and myocar-
dial ischemia. Several hurdles are, however, associated to
this kind of approach. The enthusiasm raised by pre-
clinical studies has been somehow dampened by clinical
practice, according to which the extent of cardiac repair
upon EPC inoculation is inadequate as compared to ani-
mal models. For example, intra-artery delivery of CD133+
EPCs after an acute coronary syndrome led to a 5% eleva-
tion in LVEF and reduced volume expansion beyond that
provided by state-of-the-art surgical and/or pharmacolo-
gical therapy as assessed by subsequent meta-analyses
[18,19,22,47]. The survival benefit of EPC infusion on
patients surviving to AMI is, therefore, much less
impressive than expected from regenerative therapy,
albeit clinically helpful. Moreover, injection of total BM
mononuclear cells into the heart of infarcted rats has
been shown to induce severe intramyocardial calcifica-
tions in a pre-clinical study [39]. Moreover, EPCs have
been shown to transdifferentiate into smooth muscle
cells in vivo, thereby contributing to enhance intimal
hyperplasia upon balloon injury [39,48]. These evidences
indicate that EPCs may acquire a phenotype other than
the endothelial lineage, a feature which may potentially
hamper their regenerative efficacy and harm patient
health. The current limitations in autologous EPCs-based
therapy have so far been ascribed to a number of causes,
which include: 1) the amount of blood volume (12 L)
required to isolate a therapeutically sufficient amount of
EPCs (0.5~2.0 ... 104 human EPCs/g body weight) [45]; 2)
the low percentage (10%) of EPCs retention and survival
within the injury site [19,22]; 3) the hostile microenviron-
ment in the target organ after AMI, characterized
by inflammation, fibrosis, and inadequate angiogenesis
[27]; 4) the variability in the EPC subtype that has been
transplanted into ischemic patients; 5) our poor compre-
hension of the molecular mechanisms driving EPC prolif-
eration, homing and differentiation into mature ECs in
vivo, as most of the studies in the filed have been carried
out to evaluate on their potential application in medicine,
rather than to shed light on their biology. Finally, all clin-
ical trials enrolled patients with AMI who had undergone
primary angioplasty and stent implantation to re-expand
the infarct-related artery, and cells were delivered intra-
coronary by using the stop-flow balloon catheter strategy.
In this regard, the clinical studies differed significantly
from the animal studies, where the artery was not reper-
fused and cells were directly injected into the myocar-
dium. In addition, preclinical animal models, apart from
the ischemic injury caused by ligation of the coronary
artery, are usually young and healthy. Conversely, human
subjects with chronic ischemic diseases (end-stage heart
failure and PAD) suffer from a number of co-morbidities
that may attenuate the innate reparative properties of
stem cells. Indeed, ageing and male individuals have
lower CD34+/VEGFR-2+ EPCs than their younger coun-
terparts [25,26]; moreover, the pro-angiogenic activity of
senescent EPCs is severely impaired, the decline in their
clonogenic potential occurring at an earlier age as respect
to their migratory activity [49]. It is, therefore, not sur-
prising that 1) EPCs harvested from older rats failed to
promote neovascularisation in a corneal micropocket
assay implanted into younger mice and 2) EPCs isolated
from older patients with clinical ischemia were less effec-
tive in rescuing mice hind limb ischemia as compared to
those from younger ischemic patients [27,50]. It appears
that the most promising strategy to harness autologous
EPCs in CBT is to rejuvenate their regenerative potential
by genetically intervening on the signal transduction
pathways driving cell proliferation, migration, and differ-
entiation [51,52]. Enhancing their capability of perceiving
and translating pro-angiogenic inputs, such as those pro-
vided by VEGF and SDF1-a, into a therapeutically rele-
vant biological response will open a new avenue in the
treatment of cardiovascular diseases in elderly. This
requires a careful comparison of the molecular mechan-
isms responsible for DNA synthesis and motility between
PB-derived EPCs and EPCs harvested from umbilical
cord blood (UCB), which display a higher proliferation
capacity and express higher levels of telomerase. In addi-
tion, the choice of the most effective reparative pheno-
type, while ensuring optimal cell delivery, dosing, and
timing of intervention, is essential to ensure the success-
ful outcome of such novel therapeutic approach. ECFC
stand out among the most suitable candidates for cellu-
lar-based therapeutics due to their ability to stimulate
local angiogenesis through paracrine signalling and phy-
sically engraft within neovessels. Central to the goal of
the present review, UCB-derived ECFCs (UCB-ECFCs)
are much more amenable to CBT than their peripheral
counterparts (PB-ECFCs). First, ECFCs are much more
abundant in UCB than in PB (2.5 cells/ml vs. 0.05-0.2
cells/ml), so that adequate numbers of cells may be
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obtained to treat ischemic diseases in human patients
[20,53]. Second, telomerase activity is much more promi-
nent in UCB-ECFCs, thereby delaying their entrance into
the senescence state and enhancing their regenerative
potential [20,53]. Third, the proliferative response to
VEGF is dramatically higher in UCB-ECFCs as compared
to PB-derived cells, with up to 1000 population doublings
observed vs. 20-30 [53]. Consistent with these observa-
tions, EPCs engineered to overexpress VEGF displayed
higher proliferative and adhesion capabilities in vitro
than non-transduced cells [51,52]. In addition, when
these cells were injected into a murine model of hind
limb ischemia, both the rate of neovascularisation and
the recovery of blood flow were significantly improved as
compared with controls [51,52]. Similarly, transplantation
of VEGF gene-transduced EPCs accelerated organization
and recanalization of venous thrombi by increasing capil-
lary density at this location [51,52]. A remarkable feature
of combining gene- and cell-based therapies concerns the
number of cells employed to repair the damaged tissue.
Indeed, the dose of VEGF-overexpressing EPCs required
to achieve limb savage was 30 times lower than that uti-
lised in previous experiments conducted with naïve cells
[51,52]. These findings support the notion that the
genetic manipulation of the signaling machinery that
governs EPC bioactivity alleviates potential age-related
EPC dysfunction and meet therapeutic needs.
The Ca2+ signaling toolkit as a novel molecular
target to enhance the regenerative potential of
senescent endothelial colony forming cells
It has long been known that an increase in intracellular
Ca2+ concentration ([Ca2+]i) is a critical node in the sig-
nalling network that governs the endothelial response to
both chemical and mechanical stimuli [54,55]. In parti-
cular, calcium ions play a master role in the complex
and multistepped process of angiogenesis by regulating
endothelial proliferation, migration, adhesion to the sub-
strate, contractility and organization into capillary-like
structures [7,22,23,54]. The tight relationship between
Ca2+ dynamics and endothelial signalling is not surpris-
ing when considering that Ca2+ functions as a ubiqui-
tous intracellular second messenger involved in a myriad
of processes as diverse as fertilization, gene transcription,
bioenergetics, secretion, controlled cell death, and so on
[56]. Endothelial Ca2+ signals consist in spatially and
temporally defined changes in [Ca2+]i that represent sti-
mulus-specific Ca2+ signatures. These Ca2+ signatures are
detected, decoded and relayed to the target enzyme by a
complex toolkit of Ca2+-binding proteins, pivotal among
which are calmodulin (CaM), Ca2+/CaM-dependent
kinases (CaMKI, CaMKII and CaMKIV) and calcineurin,
that act as Ca2+ sensors [22,23,54]. Compartmentaliza-
tion is the keyword to understand the versatility of Ca2+
signalling. The Ca2+-dependent mediators are indeed
physically placed in close proximity of the cytosolic
mouth of the Ca2+ channel providing the source of the
triggering signal [56-58]. This arrangement of the Ca2+
machinery enables one single ion to regulate a multitude
of even opposite cellular processes depending of the
Ca2+-permeable conductance engaged by extracellular
stimulation. Vascular ECs, as well as other non-excitable
cell types, deliver Ca2+ signals in the form of brief transi-
ents which rapidly decay to the baseline [54,59,60]. A
prolonged elevation in [Ca2+]i may, indeed, be detrimen-
tal for the cell since a massive Ca2+ load may either
induce the pro-apoptotic cascade or cause necrosis by sti-
mulating both Ca2+-dependent proteases, such as calpain,
and endonucleases [61]. Therefore, long-term cellular
responses, such as activation of the transcriptional pro-
gramme driving cell proliferation and differentiation, are
regulated by a train of cytoplasmic Ca2+ oscillations that
persist as long as the cells are presented with the growth
factor [48,54,58]. A heterogeneous increase in [Ca2+]i is
the hallmark that features endothelial monolayers
exposed to either VEGF or EGF, whose pro-angiogenic
effect is suppressed when the intracellular Ca2+ signal is
abolished [62,63]. This firmly established notion
prompted our group to investigate for the first time
whether and how VEGF utilizes the Ca2+ machinery to
promote EPC proliferation and tubulogenesis in vitro. In
particular, we focussed our efforts on ECFCs isolated
from both peripheral and umbilical cord blood with the
aim to search for differences in the components of the
Ca2+ toolkit selected by VEGF in the two cell types. At
the beginning, we found that PB-ECFCs exposed to
VEGF generate asynchronous oscillations in [Ca2+]i
which arise even in the absence of extracellular Ca2+
influx [64]. Nevertheless, Ca2+ entry is essential to main-
tain the repetitive Ca2+ spike over time. The signal trans-
duction pathway that orchestrates the oscillatory
response is initiated by the plasma membrane-bound
enzyme, phospholipase Cg (PLCg), which is enlisted by
VEGFR-2 to cleave phosphatidylinositol-4,5-bisphosphate
(PIP2), a minor phospholipid precursor, into inositol-
1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG).
InsP3 diffuses within the cytoplasm and binds to Ca
2+-
permeable InsP3 receptors (InsP3Rs) located in the
endoplasmic reticulum (ER) membranes, the largest
intracellular Ca2+ reservoir. The binding of InsP3 induces
a conformational change in InsP3R structure, thereby
causing the rhythmic Ca2+ release that shapes the first
Ca2+ transients. PB-ECFCs possess all the 3 known
InsP3R isoforms, i.e. InsP3R-1, InsP3R-2, and InsP3R-3,
the pattern of expression being InsP3R-3>InsP3R-
2>InsP3R-1 [64]. The biphasic dependence of InsP3R gat-
ing by ambient Ca2+ (<500 nM activate it, >1 μM inhibit
it) is the most likely responsible for the cyclic opening
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and closing of the channel pore in spite of the constant
levels of cytosolic InsP3 [65,66]. Alternatively, PLCg
might undergo a PKC-induced inhibition, which would
provide the feedback mechanism underpinning the peri-
odic mobilization of intralumenal Ca2+ by InsP3 [66]. The
following drop in ER Ca2+ signals the activation of a
Ca2+-permeable conductance on the plasma membrane,
which has universally been termed as store-operated
Ca2+ entry (SOCE) or capacitative Ca2+ entry (CCE)
[64,67]. Not only SOCE is the most important pathway
for Ca2+ influx in vascular endothelium, which normally
lacks voltage-gated Ca2+ channels to replenish its intra-
cellular Ca2+ pools [54]. It is the only source for Ca2+
inflow downstream PLC activation in PB-ECFCs, which
are devoid of the DAG-sensitive Canonical Transient
Receptor Potential (TRPC) channels 3 (TRPC3), TRPC6
and TRPC7 [67,68]. SOCE is mediated by the physical
interplay between Stromal Interaction Molecule-1
(Stim1), the ER Ca2+ sensor, which oligomerizes and
redistributes into sub-membranal clusters, referred to as
puncta, in response to ER emptying. Herein, Stim1 acti-
vates a Ca2+-entry route which is contributed by both
Orai1 and TRPC1, albeit it is unclear whether they all
assemble into a heteromeric ternary complex or whether
TRPC1 and Orai1 form two distinct store-operated chan-
nels [22,64,67-69]. The interplay between InsP3-depen-
dent Ca2+ discharges and SOCE shapes the oscillatory
Ca2+ response to VEGF we observed in circulating
ECFCS. NF-B provides the mechanistic link between
the train of Ca2+ transients elicited by VEGF and its sti-
mulatory effect on PB-ECFC proliferation and tubulogen-
esis in Matrigel plugs [64]. In absence of extracellular
stimulations, NF-B is retained in the cytosol by the
complex with the inhibitory protein, IkB, which masks its
nuclear localization signals (NLS) [22]. Oscillations in
[Ca2+]i promote a phosphorylation cascade which is
mediated by Ca2+/CaM-dependent protein kinases and
leads IkB to site-specific ubiquitination and subsequent
degradation. Consequently, NF-B is released from inhi-
bition and translocates into the nucleus, where it acti-
vates the transcriptional programme responsible for cell
survival and proliferation [22]. Earlier work has suggested
that periodic Ca2+ signals encode information in a ‘digi-
tal’ manner, whereby the increasing strength of an extra-
cellular stimulus results in an increasing frequency, but
not amplitude, of intracellular Ca2+ spiking [58,66]. Con-
versely, the stochastic nature of VEGF-induced Ca2+
oscillations in ECFCs indicates that they cannot be
regarded as a simple digital read-out of cell stimulation.
More recent studies disclosed that the sub-cellular spatial
profile of the Ca2+ transient might be crucial in recruiting
specific Ca2+-dependent targets by repetitive Ca2+ waves
[58]. For instance, Ca2+ microdomains arising within a
few nanometers of Orai1, rather than InsP3Rs-dependent
global Ca2+ oscillations, selectively engage the transcrip-
tional programme responsible for mast cell activation by
leukotriene C4 [57,58,70]. Needless to say, the opposite
mechanism might well be true in PB-ECFCs, with
InsP3Rs boosting cell proliferation and tubulogenesis and
SOCE being only involved in ER recharging. The next
step was to examine the [Ca2+]i elevation ignited by
VEGF in UCB-ECFCs. The higher proliferative response
manifested by the latter respect to their peripheral coun-
terparts prompted us to expect a difference in the
kinetics of the Ca2+ signal. We were, therefore, surprise
to observe a similar pattern of Ca2+ oscillations which
were not synchronized between adjacent/neighbouring
cells even from the same microscopic field of view
(manuscript submitted). A major breakthrough in our
studies was the discovery that the Ca2+ response to
VEGF does not arise when UCB-ECFCs are stimulated in
the absence of extracellular Ca2+. In other words, Ca2+
entry plays a primary role in these cells, by triggering
their oscillatory activity in the presence of VEGF, while
its role in their peripheral counterparts is limited to
maintain the Ca2+ transients over time. Similar to PB-
ECFCs, however, the Ca2+ machinery involved was placed
downstream PLCg activation, a feature implying InsP3
and/or DAG involvement (manuscript submitted). We
utilised quantitative real time-polymerase chain reaction
(qRT-PCR) analyses and immunoblotting to search for
conductances other than SOCE in UCB-ECFCs and
found that they express TRPC3 [67]. TRPC3 is as DAG-
sensitive, Ca2+-permeable channel, which is activated
independently on PKC and is implicated in the well
known effect exerted by VEGF on cell proliferation,
migration and permeability in mature endothelium
[54,71]. We exploited the small interfering-RNA techni-
que to genetically suppress its expression and assess its
contribution to VEGF-induced Ca2+ oscillations. The
results were clear-cut: VEGF does not activate any
detectable increase in [Ca2+]i in TRPC3-deficient cells
(manuscript submitted). The signalling transduction
pathway recruited by TRPC3-mediated Ca2+ entry was
not different from that dissected in PB-ECFCs and
involved the interaction between InsP3-dependent Ca
2+
release and SOCE. Intriguingly, UCB-ECFCs are not
endowed with InsP3R1, whereas they express the other
two isoforms present in ECFCs harvested from PB
(manuscript submitted). This feature is rather intriguing,
InsP3R2 being the most suitable receptor subtype to
drive repetitive Ca2+ spikes due to its peculiar InsP3 and
Ca2+-sensitivity [72]. Albeit the triggering role of TRPC3
remains to be fully elucidated, we speculate that TRPC3-
induced Ca2+ entry might favour InsP3 production by
enhancing the rate of PLCg engagement by VEGFR-2.
Accordingly, TRPC3 has been shown to induce elicit
translocation towards the plasma membrane and
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subsequent activation of the Ca2+-sensitive PLCg in anti-
gen-stimulated DT40 B lymphocytes, a process which is
suppressed by either pharmacological and genetic TRPC3
down-regulation [73]. We suggest that the amount of
InsP3 synthesized immediately after VEGFR-2 activation
is not sufficient to initiate the intracellular Ca2+ spikes,
either because of scarce PLCg recruitment to the plasma
membrane or rapid InsP3 metabolism. However, DAG,
which is generated along with InsP3, gates TRPC3 to pro-
vide the source of Ca2+ necessary to further stimulate
PLCg and trigger the first Ca2+ pulse in an InsP3-sensitive
manner. The following reduction in ER Ca2+ levels will
then activate SOCE. This positive feedback between
PLCg, DAG, TRPC3, InsP3R and SOCE occurs through-
out the oscillatory signal and underpins UCB-prolifera-
tion; indeed, the rate of cell growth is dramatically
impaired upon suppression of VEGF-induced Ca2+ oscil-
lations (manuscript submitted). Altogether, these findings
clearly indicate that juvenile ECFCs may select among a
different set of Ca2+ entry/release pathway as compared
to their older, i.e. circulating, counterparts. This is the
first mechanistic difference ever observed between the
two cell types and we are currently investigating how
TRPC3 expression impact on their pro-angiogenic activ-
ity. Our working hypothesis is that TRPC3-gated Ca2+
inflow contributes to enhance their proliferative response
to VEGF, thereby rendering their phenotype more prone
to cellular-based strategies than peripheral cells. The
rationale behind this speculation is that TRPC3 is selec-
tively coupled to a variety of Ca2+-dependent decoders,
which include, but are not limited to NF-kB, NFAT and
extracellular signal-regulated kinase (ERK) [74-76]. For
instance, Ca2+ entry through TRPC3 is conveyed to calci-
neurin to induce the nuclear translocation of NFAT in
HL-1 atrial myocytes, whereas Ca2+ inflow via L-type
(CaV1.2) channels is ineffective [77]. In agreement with
these findings, TRPC3 induces the expression of growth-
related genes in rat ventricular myocytes, albeit it does
not influence CaV1.2-paced cell contraction [77]. There-
fore, we suggest that TRPC3 is a suitable candidate to
reinforce the list of targets that might be exploited to
genetically manipulate EPC for CBT purposes.
Conclusion
Cellular therapeutics is regarded as the most promising
strategy for the future of cardiovascular diseases to over-
come the limits intrinsic to surgical methods, catheter
technologies and pharmacological treatments. Indeed,
with the ageing of populations and improvement in sur-
vival, increasing numbers of patients are not amenable
to revascularisation because of comorbid diseases, unsui-
table anatomy or the risk of interventional procedures.
The injection of autologous endothelial progenitor cells
in clinical practice, however, is still far from coming of
age due to the exceedingly number of concerns that
have been raised by the lack of therapeutic consistency
between pre-clinical studies and clinical trials. One of
the issues that must be solved before progressing
towards a safe application of stem and progenitor cells
in the patients is to understand whether and how is pos-
sible to rejuvenate the phenotype of senescent EPCs,
which are inadequate to meet the demands of repair
and regeneration in diseased vessels. Whereas most of
the efforts in the field have been carried out to under-
stand which EPC subset utilize, routes and methods of
cell delivery dosing, and timing of intervention, less
attention has been paid to the biological mechanisms
driving their angiogenic activity. In this regard, the dis-
covery that ECFCs, which represent the most suitable
candidates to recapitulate the vascular network in vivo,
exhibit a different blend of Ca2+ channels depending on
their source, i.e. peripheral vs. umbilical cord blood,
should boost the return to basic research. Indeed, Ca2+-
permeable channels are master regulator of angiogen-
esis, but Ca2+-mediated responses are tightly associated
to specific conductances. In other words, a global
elevation in [Ca2+]i is not sufficient to trigger a given
Ca2+-dependent reaction, such as gene transcription or
an increase in mitochondrial metabolism, if it does not
involve the Ca2+ channel intimately associated to this
process. Our finding that TRPC3 selectively initiates
the pro-angiogenic Ca2+ signal in ECFCs isolated from
umbilical cord blood, but not peripheral blood, might
contribute to understand their higher sensitivity to
VEGF. A large number of approaches are available to
transfer angiogenic genes into endothelial committed
progenitors [22,36,78]. Future work should be devoted
to assess whether the induction of TRPC3 expression
into ECFCs harvested from peripheral blood of older
patients will be able to rejuvenate their phenotype for
therapeutic purposes. This would pave the way for the
design of an alternative strategy to rescue ischemic
organs without the side effects associated to surgical
interventions on ageing subjects.
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